Week 24 HBeAg and HBsAg are better predictors of sustained response for Chinese HBeAg positive chronic hepatitis B patients receiving 48 weeks Peginterferon α-2b therapy

被引：0

作者：

Yang, Song ^{[1
]}

Xing, Huichun ^{[1
]}

Wang, Qixin ^{[2
]}

Xu, Daozhen ^{[1
]}

Cheng, Jun ^{[1
]}

机构：

[1] Beijing Ditan Hosp, Ctr Hepatol, Beijing, Peoples R China

[2] Merck & Co Inc, Beijing, Peoples R China

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

958

引用

页码：668A / 668A

页数：1

共 50 条

[41] Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
Hou, Feng-Qin
Song, Liu-Wei
Yuan, Quan
Fang, Lin-Lin
Ge, Sheng-Xiang
Zhang, Jun
Sheng, Ji-Fang
Xie, Dong-Ying
Shang, Jia
Wu, Shu-Huan
Sun, Yong-Tao
Wei, Shao-Feng
Wang, Mao-Rong
Wan, Mo-Bin
Jia, Ji-Dong
Luo, Guang-Han
Tang, Hong
Li, Shu-Chen
Niu, Jun-Qi
Zhou, Wei-dong
Sun, Li
Xia, Ning-Shao
Wang, Gui-Qiang
THERANOSTICS, 2015, 5 (03): : 218 - 226
[42] The alteration of liver function after 48-week therapy of Entecavir in HBeAg positive chronic hepatitis B patients
Sun, Haixia
Yan, Ying
Mai, Li
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 728 - 728
[43] Sustained HBeAg and HBsAg loss after longterm follow-up of HBeAg positive patients treated with peginterferon alpha-2B
Buster, Erik H.
Flink, Hajo J.
Cakaloglu, Yilmaz
Simon, Christopher
Trojan, Joerg
Tabak, Fehmi
So, Thomas M.
Feinman, Victor S.
Mach, Tomasz
Akarca, Ulus
Tielemans, Wanda C.
van Vuuren, Hanneke J.
Hansen, Bettina E.
Janssen, Harry L.
HEPATOLOGY, 2007, 46 (04) : 667A - 667A
[44] PEGINTERFERON IS SUPERIOR TO PROLONGED ENTECAVIR THERAPY FOR SEROLOGICAL RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B
Zoutendijk, Roeland
Sonneveld, Milan J.
Hansen, Bettina E.
Janssen, Harry L.
HEPATOLOGY, 2011, 54 : 1023A - 1023A
[45] Association between Genotype and the HBsAg Levels at HBeAg Loss in HBeAg-positive Chronic Hepatitis B Patients Treated with Entecavir or Peginterferon Alfa-2a
Peng, Cheng-Yuan
Lai, Hsueh-Chou
Su, Wen-Pang
Lin, Chia-Hsin
Chuang, Po-Heng
Chen, Sheng-Hung
HEPATOLOGY, 2014, 60 : 1121A - 1121A
[46] ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B
Lau, G. K. K.
Marcellin, P.
Brunetto, M.
Piratvisuth, T.
Kapprell, H. -P
Messinger, D.
Popescu, M.
JOURNAL OF HEPATOLOGY, 2009, 50 : S333 - S333
[47] Combination of HBsAg Level and Hepatitis B Viral Load at Week 12 is the Best Stopping Rule for Chronic Hepatitis B, HBeAg Positive Patients Treated With Peginterferon ALPHA-2A
Phisalprapa, Pochamana
Tanwandee, Tawesak
GASTROENTEROLOGY, 2012, 142 (05) : S954 - S955
[48] Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive chronic hepatitis B
Gish, Robert G.
Lok, Anna S.
Chang, Ting-Tsung
De Man, Robert A.
Gadano, Adrian
Sollano, Jose
Han, Kwang-Hyub
Chao, You-Chen
Lee, Shou-Dong
Harris, Melissa
Yang, Joanna
Colonno, Richard
Brett-Smith, Helena
GASTROENTEROLOGY, 2007, 133 (05) : 1437 - 1444
[49] Response-guided peginterferon therapy for hbeag-positive and hbeag-negative chronic hepatitis b using hepatitis b surface antigen levels: A review
Sonneveld M.J.
Brouwer W.P.
Janssen H.L.A.
Current Hepatology Reports, 2014, 13 (3) : 250 - 255
[50] Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study
Sun, Jian
Ma, Hong
Xie, Qing
Xie, Yao
Sun, Yongtao
Wang, Hao
Shi, Guangfeng
Wan, Mobin
Niu, Junqi
Ning, Qin
Yu, Yanyan
Zhou, Huijuan
Cheng, Jun
Kang, Wenzhen
Xie, Yi
Fan, Rong
Wei, Lai
Zhuang, Hui
Jia, Jidong
Hou, Jinlin
JOURNAL OF HEPATOLOGY, 2016, 65 (04) : 674 - 682

← 1 2 3 4 5 →